Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) monotherapy has shown promising results thus far, although development of resistance is a clinical challenge. The objective of this study was to cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanly, Elyse K., Tuli, Neha Y., Bednarczyk, Robert B., Suriano, Robert, Geliebter, Jan, Moscatello, Augustine L., Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890996/
https://www.ncbi.nlm.nih.gov/pubmed/26735176
http://dx.doi.org/10.18632/oncotarget.6779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890996/
https://www.ncbi.nlm.nih.gov/pubmed/26735176
http://dx.doi.org/10.18632/oncotarget.6779

Ejemplares similares